Core Insights - The event highlighted the collaboration between Premier Graphene Inc. and HGI Industrial Technologies, focusing on the future of cannabis, industrial hemp, and advanced materials science in Mexico [1][2] - Premier Graphene has secured a significant regulatory milestone with an official importing license from COFEPRIS, allowing for the importation and commercialization of cannabinoid products [2][4] - The forum discussed advancements in industrial hemp composites and medical applications, positioning Premier and HGI at the forefront of biotechnology and materials science [3][8] Regulatory Developments - Premier's relationship with Santa Rosa Green Seeds enhances its market position, particularly with the exclusive importing license from COFEPRIS [2][11] - HGI Industrial Technologies has obtained the Amparo, enabling it to legally initiate operations in compliance with Mexican regulations [4][10] - The recent executive order by President Donald Trump reclassifying cannabis may significantly impact the cannabis industry, promoting research and development [5][6] Technological Innovations - Dr. Stuart Titus emphasized the potential of cannabinoids in bioelectric medicine, particularly in cancer treatment through targeted drug delivery systems using CBD-doped graphene [3][7] - The integration of cannabinoids and graphene is seen as a new frontier in bioelectric medicine, enhancing cellular communication and restoring healthy electrical signaling [7][8] Market Positioning - Premier Graphene is committed to addressing the needs of the defense and technology sectors while aiming to fill the global gap in graphene production [8][9] - HGI Industrial Technologies is positioned to become a leading importer and developer of legal cannabinoid products in Mexico, leveraging its expertise in cultivation and regulatory compliance [10][11]

Core Insights - Speculation regarding President Trump's potential policy changes on cannabis classification led to temporary increases in cannabis stock prices, including Trulieve Cannabis, Curaleaf Holdings, Tilray Brands, and Green Thumb Industries [1] - On December 18, Trump signed an executive order that facilitates the rescheduling of marijuana, which is significant for the regulatory landscape affecting marijuana businesses [3] - Following the announcement, cannabis stocks experienced a sharp sell-off, raising questions about potential buying opportunities [3] Regulatory Changes - The U.S. drug policy is governed by the Controlled Substances Act (CSA), which classifies substances into five schedules based on their criteria [4] - The executive order reclassifies marijuana from a Schedule I narcotic to a Schedule III substance, aligning it with anabolic steroids and ketamine [5] - This reclassification could reduce barriers for cannabis companies in clinical research and financial regulation, potentially improving banking relationships [9] Industry Implications - Rescheduling marijuana to Schedule III may lead to enhanced integration of cannabis and CBD into modern medicine, opening avenues for partnerships between cannabis companies and pharmaceutical firms [9]

Core Viewpoint - Tilray Brands, Inc. will announce its financial results for the second quarter of fiscal year 2026 on January 8, 2026, after market close [1] Group 1: Financial Results Announcement - The financial results will cover the period ending November 30, 2025 [1] - A live conference call and audio webcast will be held on the same day at 4:30 PM Eastern Time to discuss these results [2] - Investors can submit questions via Robinhood and Say Technologies until January 7, 2026 [2] Group 2: Company Overview - Tilray is a leading global lifestyle and consumer packaged goods company with operations in multiple regions including Canada, the United States, Europe, Australia, and Latin America [3] - The company focuses on cannabis, beverage, wellness, and entertainment sectors, aiming to elevate lives through moments of connection [3] - Tilray supports over 40 brands in more than 20 countries, offering a range of products including cannabis, hemp-based foods, and craft beverages [3]

Core Viewpoint - Organigram Global Inc. (OGI) has shown robust growth and operating leverage, leading to margin expansion, which justifies a buy rating initiated last August. The stock has increased by 31% since the rating due to solid Q4 performance [1]. Company Analysis - The company has demonstrated strong growth metrics, contributing to a favorable investment outlook. The increase in stock price reflects positive market sentiment and operational efficiency [1]. Market Trends - The analysis highlights the importance of thorough research and understanding of financial statements and market trends, which are critical for identifying undervalued investment opportunities in mid and small-cap companies [1].

Core Viewpoint - Tilray Brands, Inc. is set to release its financial results for the second fiscal quarter ending November 30, 2025, on January 8, 2026, after market close [1] Group 1: Financial Results Announcement - The financial results will be announced after the financial markets close on January 8, 2026 [1] - A live conference call and audio webcast will be held at 4:30 PM Eastern Time on the same day to discuss these results [2] Group 2: Investor Engagement - Investors can submit and upvote questions via Robinhood and Say Technologies from now until January 7, 2026 [3] - Questions can be submitted on the Tilray stock detail page on Robinhood or through the Say Technologies platform [3] Group 3: Company Overview - Tilray is a leading global lifestyle and consumer packaged goods company with operations in multiple regions including Canada, the United States, Europe, Australia, and Latin America [3] - The company focuses on cannabis, beverage, wellness, and entertainment sectors, aiming to elevate lives through moments of connection [3] - Tilray supports over 40 brands in more than 20 countries, offering a range of products including cannabis offerings, hemp-based foods, and craft beverages [3]

Rescheduling Cannabis from Schedule I to Schedule III will help to foster a fair and supportive environment for the industry and reduce unnecessary obstacles to growthLAS VEGAS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Planet 13 Holdings, Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, is sharing the following commentary regarding the December 18, 2025 Executive Order that directs the Attorney General to expedite completion of the process ...

Core Insights - 420 Investor was launched in 2013, coinciding with Colorado's legalization of cannabis for adult use, and has now transitioned its services to Seeking Alpha [1] - Alan Brochstein, a pioneer in cannabis investment analysis, has extensive experience in the financial sector and has been focusing on cannabis stocks since 2013 [1] - The investing group 420 Investor covers 20 cannabis stocks, providing investment news, earnings report previews, and post-report analyses [1] Company and Industry Overview - 420 Investor offers a range of resources including model portfolios, weekly videos with chart analysis, summary pieces, a monthly newsletter, and a chat feature for investor inquiries [1] - Alan Brochstein is also the managing partner of New Cannabis Ventures, which has been a key provider of financial information in the cannabis industry since 2015 [1]

Core Insights - Cresco Labs (CRLBF) and other US multi-state operators (MSOs) experienced a decline last week as traders took profits following news of federal cannabis rescheduling, despite a preceding sector rally leading up to the announcement [1] Group 1 - The cannabis sector saw a rally prior to the federal cannabis rescheduling news [1] - Following the announcement, Cresco Labs and other US MSOs fell as traders capitalized on profits [1]

Market Overview - Markets experienced moderate gains due to softer inflation data and stable unemployment, which renewed investor confidence in a potential 2026 rate cut by the Federal Reserve [2] - The Dow Jones Industrial Average and S&P 500 advanced, supported by broad-based sector strength, while the Nasdaq Composite rebounded, led by a tech recovery [2] Earnings Highlights - Micron Technology Inc. exceeded expectations and raised its guidance, leading to a rally in AI-related semiconductor stocks [3] - Nike Inc. shares declined after the company expressed caution regarding global demand, particularly in China, raising concerns about consumer strength [3] - FedEx Corp. reported solid quarterly results, enhancing confidence in global shipping demand, while Carnival Corp. provided optimistic forward guidance, indicating strong consumer appetite for travel [4] Sector Performance - Cyclical and dividend-paying stocks gained traction as portfolio managers positioned for a potentially lower-rate environment in 2026 [3] - Transportation and travel sectors showed resilience, with FedEx and Carnival Corp. signaling robust demand and strong bookings [4] Notable Stock Movements - Cannabis stocks, including Tilray Brands Inc. and Canopy Growth Corp., rallied following reports of potential rescheduling of marijuana by President Trump, which could ease tax burdens [6] - Carnival Corporation reported record earnings and reinstated its quarterly dividend, forecasting adjusted net income of about $3.5 billion for 2026, reflecting strong demand [7] - Caterpillar Inc. emerged as the top-performing Dow stock in 2025, rising over 62% and adding approximately $1.7 billion in value to significant stakeholders [8] Market Sentiment - JPMorgan Chase indicated that the generative-AI narrative has peaked, suggesting that 2026 will focus more on profits rather than hype, with investors likely to favor companies demonstrating clear ROI [9] - Meta Platforms Inc. is noted as the most underperforming stock among the Magnificent 7, trading about 19% below its 52-week high, with potential for a year-end rebound [10][11] - Novo Nordisk A/S faced challenges as Eli Lilly and Co. gained market share in the weight-loss drug sector, leading to a decline in Novo's stock [12]

Financial Data and Key Metrics Changes - For fiscal year 2025, the company reported total net sales of $19.1 million, a slight decrease from $19.5 million in the prior year [16][20] - The operating loss for fiscal 2025 was approximately $2.1 million, improved from a loss of $3.3 million in 2024 [6][23] - Adjusted non-GAAP EBITDA improved from a loss of $1.7 million in 2024 to a loss of $900,000 in 2025 [6][25] - Gross profit margin for the fourth quarter of fiscal 2025 was 59%, up from 54% in the prior year [21] Business Line Data and Key Metrics Changes - E-commerce direct-to-consumer sales for the fourth quarter of fiscal 2025 were $3.5 million, a 6% year-over-year decrease [16][17] - The wholesale business generated $1.2 million in net sales for the fourth quarter of fiscal 2025, a 25% increase compared to $900,000 in the same quarter of fiscal 2024 [19][20] - For fiscal year 2025, the wholesale business generated net sales of $4.5 million, up from $3.8 million in 2024 [20] Market Data and Key Metrics Changes - Distribution for the new beverage brand, Oasis, has expanded to nine states, with improving case sell-through and growing distributor engagement [7][8] - E-commerce represented 77% of total net sales for fiscal year 2025, down from 81% in the prior year [17] Company Strategy and Development Direction - The company is focused on scaling the Oasis brand responsibly while driving efficient, profitable direct-to-consumer growth [29] - The strategy includes preserving margins and capital discipline while evaluating strategic opportunities aligned with regulatory strength [29] - The company aims to capitalize on the evolving regulatory environment, particularly with the recent executive order from the White House [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position in the evolving regulatory landscape, highlighting the potential for increased demand for CBD products [12][30] - The company believes that the heavy lifting of the turnaround is largely behind them, with fiscal 2026 focused on improving financial performance [30] - Management noted that the executive order could lead to significant demand for quality CBD products, particularly among Medicare consumers [46] Other Important Information - The company eliminated over $7 million in annual accrued preferred dividend obligations, significantly improving working capital [9][26] - The company has a strong liquidity position entering calendar 2026, with cash and cash equivalents of approximately $2.2 million [26][28] - The NYSE American confirmed that all prior compliance deficiencies had been resolved, reflecting progress in financial stability [11] Q&A Session Summary Question: What will be the key driver of growth in 2026? - Management believes there are growth opportunities in both the core cbdMD brand and the beverage side, with visibility on growth through November [35] Question: Can you explain the decline in direct-to-consumer business? - Management indicated that the decline is tied to organizational changes and is trending slightly up over prior year periods [36][37] Question: What is the timeline for Medicare coverage of CBD products? - Management mentioned that a pilot program is expected to start on April 1st, with potential for significant demand increase [39][40] Question: How will the executive order impact the business? - Management views the executive order as a potential game changer, with significant demand for CBD products expected in the coming years [45][46] Question: How are you prioritizing growth investments for fiscal 2026? - Management indicated that the next quarter will likely see more investment in the Oasis side, with ongoing evaluations based on regulatory developments [66]